A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma.

[1]  M. Vannier,et al.  A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma , 2016, Pancreas.

[2]  A. Jimeno,et al.  Hedgehog signaling drives radioresistance and stroma-driven tumor repopulation in head and neck squamous cancers. , 2014, Cancer research.

[3]  D. Rimm,et al.  Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC) , 2014, PloS one.

[4]  A. Jimeno,et al.  A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins , 2013, Molecular oncology.

[5]  J. Bauman,et al.  Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. , 2013, The Lancet. Oncology.

[6]  S. Faivre,et al.  Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. , 2013, The Lancet. Oncology.

[7]  M. Lucia,et al.  Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer. , 2013, Cancer research.

[8]  C. Rudin,et al.  Phase I Study of the Hedgehog Pathway Inhibitor IPI-926 in Adult Patients with Solid Tumors , 2013, Clinical Cancer Research.

[9]  R. Ferris,et al.  Cetuximab-Activated Natural Killer and Dendritic Cells Collaborate to Trigger Tumor Antigen–Specific T-cell Immunity in Head and Neck Cancer Patients , 2013, Clinical Cancer Research.

[10]  yang-xin fu,et al.  Cetuximab-mediated tumor regression depends on innate and adaptive immune responses. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  A. Jimeno,et al.  Vismodegib in basal cell carcinoma. , 2012, Drugs of Today.

[12]  K. Ang,et al.  Glioma-associated oncogene family zinc finger 1 expression and metastasis in patients with head and neck squamous cell carcinoma treated with radiation therapy (RTOG 9003). , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Raghu Kalluri,et al.  The basics of epithelial-mesenchymal transition. , 2009, The Journal of clinical investigation.

[14]  Maria Kasper,et al.  Epidermal growth factor receptor signaling synergizes with Hedgehog/GLI in oncogenic transformation via activation of the MEK/ERK/JUN pathway. , 2009, Cancer research.

[15]  則之 五十畑.  Hedgehog and epithelial-mesenchymal transition signaling in normal and malignant epithelial cells of the esophagus , 2009 .

[16]  L. Ailles,et al.  Cancer stem cells in head and neck squamous cell cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  N. Hanna.  Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Based Therapy , 2008 .

[18]  C. Iacobuzio-Donahue,et al.  Blockade of hedgehog signaling inhibits pancreatic cancer invasion and metastases: a new paradigm for combination therapy in solid cancers. , 2007, Cancer research.

[19]  G. Dontu,et al.  Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. , 2006, Cancer research.